This comprehensive analysis confirmed substantial reductions in hepatic fat content measured by MRI-PDFF (weighted mean difference -5.8%, 95%CI: -7.1% to -4.5%), liver enzymes, and histological parameters including steatosis and inflammation scores
4.5.3 Risk communication: clarifying uncertainty Current evidence is insufficient to classify GLP-1RAs as relatively safe during pregnancy, and they should certainly not be used as a first-line treatment for gestational obesity or diabetes simply due to their weight-loss benefits (132)
But again, for those who do have PCOS and a higher weight, plenty of data suggests that the two can fuel and feed into each other
Regularly review your progress with your healthcare provider, and be proactive in adjusting your lifestyle strategies as needed
However, this paradigm is shifting as health systems recognize the substantial cardiovascular benefits demonstrated in dedicated outcomes trials
These steps apply whether someone is currently on GLP-1 medication, tapering off, or recently discontinued